Amphastar Pharma (AMPH) Tops Q3 EPS by 5c

Amphastar Pharma (NASDAQ: AMPH) reported Q3 EPS of $0.07, $0.05 better than the analyst estimate of $0.02. Revenue for the quarter came in at $57.9 million versus the consensus estimate of $57.2 million.

For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• JPMorgan Upgrades Whitehaven Coal Ltd. (WHC:AU) (WHITF) to Overweight
• UiPath Inc. (PATH) Reports In-Line Q2 EPS; offers guidance